About Oral Cancer Foundation News Team - A

This author has not yet filled in any details.
So far Oral Cancer Foundation News Team - A has created 2444 blog entries.

A story NOT silenced by oral cancer: a message to dental professionals

Source: dentistryiq Author: Eva Grayzel The storyteller gets tongue cancer? How ironic! Sharing my personal oral cancer journey publicly is a tribute to those who came before me and an obligation to those who will follow. Knowing my story will save lives. That’s why I tell it. Here it is, in a nutshell. Just a simple little sore spot It started with a sore on the left side of my tongue. A strange place for what seemed like an ordinary canker sore. After four weeks, I went to an oral surgeon, complaining of pain. He said if it bothered me so much, he could take it off. Two weeks later, the oral surgeon’s receptionist called to tell me my biopsy was negative. “Excuse me, are you calling the right patient?” I was never told about a biopsy. “The oral surgeon took tissue from your tongue, correct?” she questioned. “Yes, that was me.” I thought to myself, What could they possibly be looking for in a biopsy of the tongue? “You have nothing to worry about,” she assured me. I did not know I had to worry. She should have said my biopsy was negative for cancer. I had no idea you could get cancer in the mouth. No dental professional had ever used the word cancer in my presence. Cancer of the oral cavity was simply beyond my scope of understanding. “Nothing to worry about” Two years later, the sore returned right over the biopsy site. Eight weeks later, I [...]

2021-04-24T10:59:32-07:00April, 2021|Oral Cancer News|
Read More

Addressing unmet needs for head and neck cancer awareness month

Source: www.targetedonc.com Author: Sara Karlovitch Head and neck cancers, also known as squamous cell carcinomas of the head and neck, account for nearly 50,000 cases of cancer per year in the United States. April is head and neck cancer month. According to the American Association for Cancer Research (AACR), alcohol and tobacco use are major risk factors for developing head and neck cancers. However, infection with the cancer-causing types of the human papillomavirus (HPV) also increases the risk for certain forms of the cancer, as well as eating preserved or salted foods, poor oral hygiene, occupational exposure to wood dust, asbestos, and synthetic fibers, radiation exposure, and Epstein-Barr virus infection in endemic regions, including southeast Asia. Head and neck cancers are more common among men than women. Additionally, most patients who are diagnosed with this type of cancer are 50 years or older. Symptoms include a lump or sore on that does not go away or heal, difficulty swallowing, changes in voice, or a sore throat that does not resolve or heal. Trials such as the KEYNOTE-048 study (NCT02358031), which investigated the use of pembrolizumab (Keytruda) as a first line treatment for recurrent or metastatic squamous cell cancer of the head and neck, have changed how head and neck cancers are treated. While many patients recover, many are still affected by life-long disabilities as the result of their disease and treatment. Stuart J. Wong, MD, a medical oncologist, professor, and director of the Center for Disease Prevention Research at the [...]

2021-04-22T09:58:37-07:00April, 2021|Oral Cancer News|
Read More

How this surgery center is changing the way doctors communicate with patients

Source: foxbaltimore.com Author: WBFF staff Head and neck cancers have a variety of causes, including human papillomavirus (HPV) infection, alcohol and tobacco use, sun exposure, poor oral health, or occupational exposure to hazardous materials. Regardless of the cancer's cause, recovery often depends on how quickly a patient can begin treatment. The experience of starting treatment is of particular interest to Farzad Masroor, M.D., a surgeon at GBMC's Milton J. Dance, Jr. Head and Neck Center, and his team. "The head and neck areas are how we interface with the world," he said. "The mouth and throat are vital to talking and tasting, and when treatments focus on those areas, it will invariably affect a patient's quality of life." To help minimize the need for invasive treatments like surgery and radiation, Dr. Masroor and his colleagues prioritize early detection and care to yield the best possible outcomes. Although patients are encouraged to see their primary physicians or dermatologists before making an appointment with a surgeon, Dr. Masroor also recommends that patients refer themselves if they are concerned that cancer is present. "I would rather see my office filled with people who I can reassure about their health than have patients delay care and end up with something seriously wrong that requires a significant procedure," he said. Courtesy phone consultations with a head and neck surgeon at the Milton J. Dance, Jr. Center are available for patients in these instances. Though these are not designed to replace in-person visits, they allow patients [...]

2021-04-16T19:56:33-07:00April, 2021|Oral Cancer News|
Read More

Cancer vaccine shows early promise across tumor types

Source: www.webmd.com Author: Walter Alexander A personalized cancer vaccine proved possible to manufacture and was well tolerated in an early phase I clinical trial, researchers said. The vaccine, known as PGV-001, was given to 13 patients with solid tumors or multiple myeloma who had a high risk of recurrence after surgery or stem cell transplant. At last follow-up, four patients were still alive without evidence of disease and had not received subsequent therapy, four were alive and receiving therapy, three had died, and two could not be contacted for follow-up. Thomas Marron, MD, of Mount Sinai in New York presented these results at the American Association for Cancer Research Annual Meeting recently. “While cancer immunotherapy has revolutionized the treatment of cancer, we know that the majority of patients fail to achieve significant clinical response,” Marron said during his presentation. Personalized vaccines may help prime an improved immune response, he said. With this in mind, Marron and colleagues developed PGV-001, a vaccine consisting of customized peptides – a kind of amino acid -- given to patients along with initial treatment. Feasibility and safety Vaccines were given to 13 patients. Six had head and neck cancer, three had multiple myeloma – a cancer of the white blood cells -- two had lung cancer, one had breast cancer, and one had bladder cancer. Eleven patients received all 10 intended doses, and two patients received at least eight doses. “The vaccine was well tolerated, with only half of patients experiencing mild, grade 1 adverse [...]

2021-04-16T19:49:45-07:00April, 2021|Oral Cancer News|
Read More

Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types

Source: www.globenewswire.com Author: press release, F. Hoffmann-La Roche Ltd Roche today announced the launch of the Elecsys Anti-p53 immunoassay for the in vitro quantitative determination of anti-p53 antibodies. This test is used to aid physicians to diagnose throat cancer, bowel cancer and breast cancer in patients, in conjunction with other diagnostic tests. The assay is now available for all markets accepting the CE Mark. “The addition of our Elecsys Anti-p53 immunoassay will help clinicians to quickly and reliably diagnose several prevalent cancers and might assist in leading to a better prognosis for many patients.”, said Thomas Schinecker, CEO Roche Diagnostics. “Beyond breakthrough cancer medicines, Roche also offers a growing number of testing solutions to help physicians diagnose and treat people with cancer. p53 is protein which, when active, helps to regulate processes which stop tumors from developing. A mutation of p53 is present in half of solid tumor cancers and is the most common genetic change identified so far in human cancers.1 Certain mutations of p53 can lead to a build up of p53 which results in the formation of anti-p53 autoantibodies. Autoantibodies are antibodies that mistakenly target and react with a person’s own tissues. Between 20-50% of patients with mutated p53 will produce anti-p53 autoantibodies.2 This mutation causes the tumor suppressive function of p53 to switch to a tumor-promoting function and thus cancer development. Early appearance of anti-p53 antibodies during tumour development may have potential to detect malignant changes.3 The Elecsys Anti-p53 immunoassay detects these anti-p53 antibodies and, when [...]

2021-04-08T09:59:47-07:00April, 2021|Oral Cancer News|
Read More

Your cancer answers: can nutrition, exercise improve quality of life for head, neck cancer patients?

Source: syvnews.com Author: John Malinowski, Marian Cancer Care Question: How can nutrition and exercise improve quality of life for head and neck cancer patients? Head and neck cancers affect more than 52,000 Americans each year and account for about 5% of new cancer cases worldwide. Treatment of head and neck cancer with concurrent chemo radiotherapy with curative intent may cause side effects leading to deterioration of long-term quality of life and disability that persists years after treatment. Many head and neck cancer patients experience treatment related side effects such as; difficulty swallowing, difficulty with speech, loss of taste or smell and unintended weight loss which often can be attributed to decreased muscle mass. There are a few things that you can do to try helping to maintain your body weight during treatment. Nutrition can be one tool to help ensure you are taking in enough calories and the right nutrients to help your body fight the cancer. Often when undergoing cancer treatments our body has an increased demand of caloric intake. This can be a challenge to increase your calories while undergoing treatment so try eating several smaller meals throughout the day, maybe even every 2-3 hours. With each meal try to incorporate some carbohydrates, fats, and protein. Make sure you are intentional about chewing your food. You can try to chew each bite 50 times or trying to incorporate softer texture foods can make it easier to swallow. Steaming or boiling vegetables rather than eating raw may help. Softer [...]

2021-04-08T09:46:35-07:00April, 2021|Oral Cancer News|
Read More

Deactivating cancer cell gene boosts immunotherapy for head and neck cancers

Source: newsroom.ucla.edu Author: Brianna Aldrich By targeting an enzyme that plays a key role in head and neck cancer cells, researchers from the UCLA School of Dentistry were able to significantly slow the growth and spread of tumors in mice and enhance the effectiveness of an immunotherapy to which these types of cancers often become resistant. Their findings, published online in the journal Molecular Cell, could help researchers develop more refined approaches to combating highly invasive head and neck squamous cell cancers, which primarily affect the mouth, nose and throat. Immunotherapy, which is used as a clinical treatment for various cancers, harnesses the body’s natural defenses to combat disease. Yet some cancers, including head and neck squamous cell carcinomas, don’t respond as well to the therapy as others do. The prognosis for these head and neck cancers is poor, with a high five-year mortality rate, and there is an urgent need for effective treatments. The UCLA research team, led by distinguished professor Dr. Cun-Yu Wang, chair of oral biology at the dentistry school, demonstrated that by targeting a vulnerability in the cellular process of tumor duplication and immunity, they could affect tumor cells’ response to immunotherapy. The enzyme they focused on, KDM4A, is what is known as an epigenetic factor — a molecule that regulates gene expression, silencing some genes in cells and activating others. In squamous cell head and neck cancers, overexpression of KDM4A promotes gene expression associated with cancer cell replication and spread. It is well known that [...]

2021-03-25T13:21:05-07:00March, 2021|Oral Cancer News|
Read More

Deal-making in head and neck cancer to start yielding dividends for patients

Source: www.thepharmaletter.com Author: staff A frenzy of deal-making activity in head and neck cancer is bringing late-stage clinical candidates into view, according to GlobalData. Intelligence from the data and analytics provider shows that there have been some 340 licensing agreements since 2004 in head and neck cancer, amounting to an approximate total value of $35 billion. Aarohi Rede, oncology analyst at GlobalData, said: “The past few years have seen several licensing deals globally for clinical development in head and neck cancer. Merck KGaA’s collaboration with Debiopharm has the potential to transform the current treatment paradigm for head and neck squamous cell carcinoma (HNSCC) by combining xevinapant, a new molecular entity, with Merck KGaA’s strong commercialization capabilities.” Of the total licensing agreements signed, the highest recorded licensing agreements took place in North America, followed by Asia-Pacific, while the lowest recorded number of deals belonged to South and Central America. Dr Rede added: “Head and neck cancer is largely a chemotherapy-dominated market, but the past few years have seen effective use of Keytruda (pembrolizumab) and Bristol Myers Squibb’s Opdivo (nivolumab) in the recurrent or metastatic settings. The current clinical development pipeline has around 20 late-stage agents in the immuno-modulating therapy or cell inhibitor classes, thus revealing a robust late-stage pipeline that is highly conducive to future partnerships for licensing and commercialization, and is expected to contribute to significant market growth over the next ten years.” Many of these licensing deals involve strategic partnerships between Asia-Pacific, namely Chinese manufacturers, and US pharmaceuticals for [...]

2021-03-25T13:15:11-07:00March, 2021|Oral Cancer News|
Read More

On treating advanced head and neck cancer without cisplatin – an oncology grand rounds discussion

Source: www.medpagetoday.com Author: Mark L. Fuerst An oncology grand rounds discussion with Sachin Jhawar, MD. Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous set of diseases with different features and treatment recommendations. Physicians face challenges in initial treatment decision-making and response assessments, including the changing role of surgery, the incorporation of human papilloma and Epstein Barr virus status, as well as the potential for treatment de-escalation using patient-related and tumor-related factors. A recent "Oncology Grand Rounds" article in the Journal of Clinical Oncology provides an overview of treating advanced HNSCC when cisplatin is not an option, including concurrent chemotherapy, cetuximab, targeted therapy, and immunotherapy. In the following interview, the paper's lead author, Sachin Jhawar, MD, of Ohio State University Comprehensive Cancer Center in Columbus, reviews the main issues. What is the focus of the article? Jhawar: We focused on patients with locally advanced disease who would be receiving definitive non-surgical treatment when possible treatment with concurrent cisplatin, delivered either every 3 weeks or weekly, is always the preferred treatment. We specifically wanted to delve into the subset of patients who we would not recommend to receive cisplatin because of age or comorbidities. This could be concurrent chemotherapy (carboplatin/paclitaxel), concurrent cetuximab, and altered or standard fractionation radiation schedules without systemic therapy, as well as when to consider immunotherapy and palliative radiation for those with recurrent or metastatic disease. There is also a great deal of institutional preference involved. At our institution, we prefer concurrent carboplatin/paclitaxel in patients who cannot [...]

2021-03-19T09:09:44-07:00March, 2021|Oral Cancer News|
Read More

A new type of recyclable: Finding new uses for established drugs

Source: www.eurekalert.org Author: news release Researchers from Tokyo Medical and Dental University (TMDU) uncover potential novel therapeutic strategies for oral and esophageal carcinomas Discovering and treating tumors before they spread throughout the body is key for cancer patients to achieve positive outcomes. When tumor cells spread, which is known as metastasis, they can take over other organs and lead to death. Oral and esophageal carcinomas, or mouth and throat cancers, frequently metastasize to the lymph nodes. Unfortunately, there are currently no therapies that are specific to treating these particular cancers. Now, researchers at Tokyo Medical and Dental University (TMDU) identified several drugs that can possibly be used to treat oral and esophageal carcinomas. In an article published in Molecular Cancer Research, a group of researchers from TMDU found that combining two drugs, pitavastatin and capmatinib, inhibited the viability of oral cancer cells in culture, as well as the growth of tumors in a mouse model. Although esophageal carcinoma is the sixth most deadly cancer worldwide and is relatively well understood at the molecular level, the research has not been translated into specific therapeutic development. Because of this urgent need, the TMDU group became interested in drug repurposing, where a drug that has been approved for a certain disease can be used to effectively treat an additional indication. This concept significantly speeds up the drug discovery and development process, increasing the number of patients that can benefit from an established therapeutic. "Drug repurposing can be extremely helpful for discovering efficacious treatments [...]

2021-03-17T10:04:37-07:00March, 2021|Oral Cancer News|
Read More
© - The Oral Cancer Foundation - Head & Neck Cancer IRS 501(c)3 Charity - 3419 Via Lido #205, Newport Beach, CA 92663 | Disclaimer / Privacy Policy
Go to Top